zinc finger protein 33C, pseudogeneGenealiases: BA393J16.4 · ZNF33AP1
Q-omics provides the consensus-scored ZNF33CP profile across patient tissues and cancer cell-line models. ZNF33CP expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF33CP is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, ZNF33CP RNA expression shows 6,825 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, KIRC, and STAD as cancer lineages where ZNF33CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF33CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF33CP survival associations across molecular data types. ZNF33CP RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF33CP RNA expression–survival associations across cancer types. High ZNF33CP expression shows unfavorable associations in MESO, READ, ESCA, UVM and UCEC, but favorable associations in LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF33CP RNA expression.
This table summarizes ZNF33CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF33CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF33CP shows lower tumor expression in THCA, LUAD and STAD and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher ZNF33CP RNA expression in tumor versus normal tissue (log2 FC = +0.167, t-test p < 0.001).
This table shows molecular features associated with ZNF33CP in patient tissues and cancer cell lines. In patient samples, ZNF33CP shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
